Drostanolone Propionate
Status
No approved product. No current FDA-approved labeling. Drostanolone propionate was formerly marketed for advanced breast cancer and is no longer approved or marketed in the United States. Schedule III controlled substance.
What it is
A short-acting DHT-derived steroid once used in oncology.
What published research measured
A dihydrotestosterone-derived injectable steroid formerly used as an adjunct in advanced breast cancer, which is the origin of its limited clinical literature. Because it derives from dihydrotestosterone it does not aromatize to oestrogen, and it has weak anti-oestrogenic activity of its own — the pharmacological basis for its historical oncology use and for the physique reputation that followed. The corollary is that it is strongly androgenic relative to its anabolic effect, and the published adverse effects follow from that: androgenic alopecia in susceptible individuals, acne, and virilization in women at low exposures. It suppresses the gonadal axis like the rest of the class. Prohibited at all times under WADA class S1.1.
Source
Borodi G et al. 2020 — Exploring the Polymorphism of Drostanolone Propionate · Chowdhury MS et al. 1976 — A comparison of drostanolone propionate (Masteril) and nandrolone decanoate (Deca-durabolin) in the treatment of brea… · Gheddar L et al. 2023 — The Power of Keratinous Matrices (Head Hair, Body Hair and Nail Clippings) Analysis in a Case of Death Involving Anab…
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.